Clinical Trial

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

Study acronym: CLEAR
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-07-17; most recent amendment 2026-07-01.
Status change: Not Yet Recruiting → Recruiting 2025-11-21
Trial Details
NCT Number NCT07088926
Lead Sponsor AstraZeneca
Conditions Bronchiectasis With Pseudomonas Aeruginosa Colonization
Enrollment 435 participants
Start Date 2025-11-06
Primary Completion 2027-12-09 (estimated)
Study Completion 2028-06-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-31